Immunomodulatory drugs: New options for the treatment of myelodysplastic syndromes

Clinical Lymphoma, Myeloma and Leukemia

Volumn 13, Issue 1, 2013, Pages 1-7

  Castelli, Roberto ^a   Cassin, Ramona ^a   Cannavò, Antonino ^a   Cugno, Massimo ^a  

^a UNIVERSITY OF MILAN   (Italy)

Author keywords

5q deletions; Hematologic malignancies; Immunomodulatory drugs; Lenalidomide; Myelodysplastic syndromes; Thalidomide

Indexed keywords

ANTIBIOTIC AGENT; AZACITIDINE; IMMUNOMODULATING AGENT; LENALIDOMIDE; POMALIDOMIDE; RECOMBINANT ERYTHROPOIETIN; THALIDOMIDE;

ACUTE GRANULOCYTIC LEUKEMIA; ANEMIA; ANTIBIOTIC PROPHYLAXIS; BACTERIAL INFECTION; BIRTH DEFECT; BLEEDING; BONE MARROW SUPPRESSION; BRAIN HEMORRHAGE; CARDIOTOXICITY; CHROMOSOME 5Q; CHROMOSOME DELETION 5; CONSTIPATION; DEEP VEIN THROMBOSIS; DESQUAMATION; DIARRHEA; DISEASE FREE SURVIVAL; DIZZINESS; DRUG EFFICACY; DRUG ERUPTION; DRUG MECHANISM; DRUG SAFETY; FATIGUE; FEBRILE NEUTROPENIA; HIGH RISK POPULATION; HUMAN; IMMUNOMODULATION; INJECTION SITE REACTION; LOW DRUG DOSE; MULTIPLE CYCLE TREATMENT; MYELODYSPLASTIC SYNDROME; NEUTROPENIA; PROGNOSIS; QUALITY OF LIFE; REVIEW; SEPSIS; SEPTIC SHOCK; SOMNOLENCE; SURVIVAL RATE; SYSTEMATIC REVIEW; THROMBOCYTOPENIA; THROMBOEMBOLISM; THROMBOSIS;

HUMANS; IMMUNOLOGIC FACTORS; LYMPHOCYTE ACTIVATION; MYELODYSPLASTIC SYNDROMES; THALIDOMIDE;

EID: 84873299695     PISSN: 21522650     EISSN: 21522669     Source Type: Journal    
DOI: 10.1016/j.clml.2012.09.016     Document Type: Review

References (59)

1. C.R. Cogle, B.M. Caig, D.E. Rollison Incidence of the myelodysplastic syndromes using a novel claims-based algorithm: high number of uncaptured cases by cancer registries Blood 7 2011 7121 7125
2. A. Tefferi, J.W. Vardiman Myelodysplastic syndromes N Engl J Med 361 2009 1872 1885
3. P. Greenberg, C. Cox, M.M. LeBeau International scoring system for evaluating prognosis in myelodysplastic syndromes Blood 89 1997 2079 2088
4. L. Malcovati, U. Germing, A. Kuendgen Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes J Clin Oncol 25 2007 3503 3510
5. A. Szmigielska-Kapon, T. Robak Hypomethylating agents in the treatment of myelodysplastic syndromes and myeloid leukemia Curr Cancer Drug Targets 11 2011 837 848
6. D. Haase, U. Germing, J. Schanz New insights into the prognostic impact of the karyotype in MDS and correlation with subtypes: evidence from a core dataset of 2124 patients Blood 110 2007 4385 4395
7. P. Bernasconi, C. Klersy, M. Boni World Health Organization classification in combination with cytogenetic markers improves the prognostic stratification of patients with de novo primary myelodysplastic syndromes Br J Haematol 137 2007 193 205
8. F. Solé, E. Luño, C. Sanzo Identification of novel cytogenetic markers with prognostic significance in a series of 968 patients with primary myelodysplastic syndromes Haematologica 90 2005 1168 1178
9. H. Van den Berghe, J.J. Cassiman, G. David Distinct haematological disorder with deletion of long arm of no. 5 chromosome Nature 251 1974 437 438
10. M. Cazzola Myelodysplastic syndrome with isolated 5q deletion (5q- syndrome) A clonal stem cell disorder characterized by defective ribosome biogenesis Haematologica 93 2008 967 972
11. A.F. List Emerging data on IMiDs in the treatment of myelodysplastic syndromes (MDS) Semin Oncol 32 suppl 2005 S31 S35
12. A. Aguayo, F.M. Armillas-Canseco, D. Martínez-Baños Antiangiogenesis in myelodysplastic syndrome Curr Cancer Drug Targets 11 2011 1044 1052
13. M. Askmyr, J. Quach, L.E. Purton Effects of the bone marrow microenvironment on hematopoietic malignancy Bone 48 2011 115 120
14. L. Adès, P. Fenaux Immunomodulating drugs in myelodysplastic syndromes Hematology Am Soc Hematol Educ Program 2011 2011 556 560
15. G. Iyer, J. Languillon, K. Ramanujam WHO co-ordinated short-term double-blind trial with thalidomide in the treatment of acute lepra reactions in male lepromatous patients Bull World Health Organ 45 1971 719 732
16. A. Palumbo, K. Anderson Multiple myeloma N Engl J Med 364 2011 1046 1060
17. R. Castelli, A. Cannavò, F. Conforti Immunomodulatory drugs in multiple myeloma: from molecular mechanisms of action to clinical practice Immunopharmacol Immunotoxicol 34 2012 740 753
18. N. Tageja Lenalidomide: current understanding of mechanistic properties Anticancer Agents Med Chem 11 2011 315 326
19. M.Q. Lacy, S.V. Rajkumar Pomalidomide: a new IMiD with remarkable activity in both multiple myeloma and myelofibrosis Am J Hematol 85 2010 95 96
20. L. Balducci Transfusion independence in patients with myelodysplastic syndromes: impact on outcomes and quality of life Cancer 106 2006 2087 2094
21. D.L. Patrick, D.D. Gagnon, M.J. Zagari Assessing the clinical significance of health-related quality of life (HrQOL) improvements in anaemic cancer patients receiving epoetin alfa Eur J Cancer 39 2003 335 345
22. M. Clavio, F. Nobili, E. Balleari Quality of life and brain function following high-dose recombinant human erythropoietin in low-risk myelodysplastic syndromes: a preliminary report Eur J Haematol 72 2004 113 120
23. E. Hellström-Lindberg Efficacy of erythropoietin in the myelodysplastic syndromes: a meta-analysis of 205 patients from 17 studies Br J Haematol 89 1995 67 71
24. R.S. Negrin, R. Stein, K. Doherty Maintenance treatment of the anemia of myelodysplastic syndromes with recombinant human granulocyte colony-stimulating factor and erythropoietin: evidence for in vivo synergy Blood 87 1996 4076 4081
25. S. Park, S. Grabar, C. Kelaidi GFM group (Groupe Francophone des Myélodysplasies) Predictive factors of response and survival in myelodysplastic syndrome treated with erythropoietin and G-CSF: the GFM experience Blood 111 2008 574 582
26. F. Zorat, V. Shetty, D. Dutt The clinical and biological effects of thalidomide in patients with myelodysplastic syndromes Br J Haematol 115 2001 881 894
27. R. Invernizzi, E. Travaglino, M. De Amici Thalidomide treatment reduces apoptosis levels in bone marrow cells from patients with myelodysplastic syndromes Leuk Res 29 2005 641 647
28. J. Tamburini, C. Elie, S. Park Groupe Francophone des Myélodysplasies, GFM Effectiveness and tolerance of low to very low dose thalidomide in low-risk myelodysplastic syndromes Leuk Res 33 2009 547 550
29. C. Kelaidi, S. Park, S. Brechignac Groupe Francophone des Myélodysplasies (GFM) Treatment of myelodysplastic syndromes with 5q deletion before the lenalidomide era; the GFM experience with EPO and thalidomide Leuk Res 32 2008 1049 1053
30. A.K. Gandhi, J. Kang, S. Naziruddin Lenalidomide inhibits proliferation of Namalwa CSN.70 cells and interferes with Gab1 phosphorylation and adaptor protein complex assembly Leuk Res 30 2006 849 858
31. A. Matsuoka, A. Tochigi, M. Kishimoto Lenalidomide induces cell death in an MDS-derived cell line with deletion of chromosome 5q by inhibition of cytokinesis Leukemia 24 2010 748 755
32. A.A. Giagounidis, U. Germing, C. Strupp Prognosis of patients with del(5q) MDS and complex karyotype and the possible role of lenalidomide in this patient subgroup Ann Hematol 84 2005 569 571
33. D. Sibon, G. Cannas, F. Baracco Groupe Francophone des Myélodysplasies Lenalidomide in lower-risk myelodysplastic syndromes with karyotypes other than deletion 5q and refractory to erythropoiesis-stimulating agents Br J Haematol 156 2012 619 625
34. A. List, S. Kurtin, D.J. Roe Efficacy of lenalidomide in myelodysplastic syndromes N Engl J Med 352 2005 549 557
35. A. List, G. Dewald, J. Bennett Myelodysplastic syndrome-003 study investigators Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion N Engl J Med 355 2006 1456 1465
36. P. Fenaux, A. Giagounidis, D. Selleslag A randomized phase 3 study of lenalidomide versus placebo in RBC transfusion-dependent patients with low-/Intermediate-1-risk myelodysplastic syndromes with del5q Blood 118 2011 3765 3776
37. F. Le Bras, M. Sebert, C. Kelaidi Treatment by lenalidomide in lower risk myelodysplastic syndrome with 5q deletion: the GFM experience Leuk Res 35 2011 1444 1448
38. D.H. Chang, N. Liu, V. Klimek Enhancement of ligand-dependent activation of human natural killer T cells by lenalidomide: therapeutic implications Blood 108 2006 618 621
39. A.C. Chan, P. Neeson, E. Leeansyah Testing the NKT cell hypothesis in lenalidomide-treated myelodysplastic syndrome patients Leukemia 24 2010 592 600
40. M. Ximeri, A. Galanopoulos, M. Klaus Hellenic MDS Study Group Effect of lenalidomide therapy on hematopoiesis of patients with myelodysplastic syndrome associated with chromosome 5q deletion Haematologica 95 2010 406 414
41. L. Adès, S. Boehrer, T. Prebet Efficacy and safety of lenalidomide in intermediate-2 or high-risk myelodysplastic syndromes with 5q deletion: results of a phase 2 study Blood 113 2009 3947 3952
42. L. Möllgård, L. Saft, M.B. Treppendahl Clinical effect of increasing doses of lenalidomide in high-risk myelodysplastic syndrome and acute myeloid leukemia with chromosome 5 abnormalities Haematologica 96 2011 963 971
43. E.H. Estey Acute myeloid leukemia: 2012 update on diagnosis, risk stratification, and management Am J Hematol 87 2012 89 99
44. J. Schecter, N. Galili, A. Raza Refining existing therapy improved biologic insights Bloods Rev 26 2012 73 80
45. M.A. Sekeres, A.F. List, D. Cuthbertson Phase I combination trial of lenalidomide and azacitidine in patients with higher-risk myelodysplastic syndromes J Clin Oncol 28 2010 2253 2258
46. E. Scherman, S. Malak, C. Perot Interest of the association azacitidine-lenalidomide as frontline therapy in high-risk myelodysplasia or acute myeloid leukemia with complex karyotype Leukemia 26 2012 822 824
47. M.A. Dimopoulos, A. Palumbo, M. Attal European myeloma network Optimizing the use of lenalidomide in relapsed or refractory multiple myeloma: consensus statement Leukemia 25 2011 749 760
48. M. Cavo, E. Zamagni, C. Cellini Deep-vein thrombosis in patients with multiple myeloma receiving first-line thalidomide-dexamethasone therapy Blood 100 2002 2272 2273
49. T. Barbui, A. Falanga Thalidomide and thrombosis in multiple myeloma J Thromb Haemost 1 2003 421 422
50. S.L. Scarpace, T. Hahn, H. Roy Arterial thrombosis in four patients treated with thalidomide Leuk Lymphoma 46 2005 239 242
51. R. Castelli, B. Ferrari, A. Cortelezzi Thromboembolic complications in malignant haematological disorders Curr Vasc Pharmacol 8 2010 482 494
52. A. Corso, A. Lorenzi, V. Terulla Modification of thrombomodulin plasma levels in refractory myeloma patients during treatment with thalidomide and dexamethasone Ann Hematol 83 2004 588 591
53. G. Aue, J. Nelson Lozier, X. Tian Inflammation, TNFα and endothelial dysfunction link lenalidomide to venous thrombosis in chronic lymphocytic leukemia Am J Hematol 86 2011 835 840
54. M. Cugno, M.O. Borghi, L.M. Lonati Patients with antiphospholipid syndrome display endothelial perturbation J Autoimmun 34 2010 105 110
55. S. Valsami, W. Ruf, M.S. Leikauf Immunomodulatory drugs increase endothelial tissue factor expression in vitro Thromb Res 127 2011 264 271
56. A. Hoshi, A. Matsumoto, J. Chung Activation of coagulation by a thalidomide-based regimen Blood Coagul Fibrinolysis 22 2011 532 540
57. B.K. Hadland, G.D. Longmore Erythroid-stimulating agents in cancer therapy: potential dangers and biologic mechanisms J Clin Oncol 27 2009 4217 4226
58. A.E. Lichtin Clinical practice guidelines for the use of erythroid-stimulating agents: Asco, EORTC, NCCN Cancer Treat Res 157 2011 239 248
59. L. Adès, F. Le Bras, M. Sebert Treatment with lenalidomide does not appear to increase the risk of progression in lower risk myelodysplastic syndromes with 5q deletion A comparative analysis by the Groupe Francophone des Myelodysplasies Haematologica 97 2012 213 218